Aoki K, Nakamura H, Suzuki H, Matsuo K, Kataoka K, Shimamura T, Motomura K, Ohka F, Shiina S, Yamamoto T, Nagata Y, Yoshizato T, Mizoguchi M, Abe T, Momii Y, Muragaki Y, Watanabe R, Ito I, Sanada M, Yajima H, Morita N, Takeuchi I, Miyano S, Wakabayashi T, Ogawa S, Natsume A (2018) Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro-Oncol 20:66–77. https://doi.org/10.1093/neuonc/nox132

Article  PubMed  CAS  Google Scholar 

Appay R, Dehais C, Maurage C-A, Alentorn A, Carpentier C, Colin C, Ducray F, Escande F, Idbaih A, Kamoun A, Marie Y, Mokhtari K, Tabouret E, Trabelsi N, Uro-Coste E, Delattre J-Y, Figarella-Branger D, Network POLA (2019) CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro-Oncol noz124. https://doi.org/10.1093/neuonc/noz124

Article  Google Scholar 

Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Bullard DE, Mehta MP, Gilbert MR, Brown PD, Stelzer KJ, McElroy JP, Fleming JL, Timmers CD, Becker AP, Salavaggione AL, Liu Z, Aldape K, Brachman DG, Gertler SZ, Murtha AD, Schultz CJ, Johnson D, Laack NN, Hunter GK, Crocker IR, Won M, Chakravarti A (2020) Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: a phase III trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. J Clin Oncol 38:3407–3417. https://doi.org/10.1200/JCO.19.02983

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bortolotto S, Chiadò-Piat L, Cavalla P, Bosone I, Chiò A, Mauro A, Schiffer D (2000) CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas. Int J Cancer 88:554–557. https://doi.org/10.1002/1097-0215(20001115)88:4<554::aid-ijc6>3.0.co;2-q

Article  PubMed  CAS  Google Scholar 

Brat DJ, Aldape K, Colman H, Figrarella-Branger D, Fuller GN, Giannini C, Holland EC, Jenkins RB, Kleinschmidt-DeMasters B, Komori T, Kros JM, Louis DN, McLean C, Perry A, Reifenberger G, Sarkar C, Stupp R, Van Den Bent MJ, Von Deimling A, Weller M (2020) cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol (Berl) 139:603–608. https://doi.org/10.1007/s00401-020-02127-9

Article  PubMed  Google Scholar 

Burns KL, Ueki K, Jhung SL, Koh J, Louis DN (1998) Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas. J Neuropathol Exp Neurol 57:122–130. https://doi.org/10.1097/00005072-199802000-00003

Article  PubMed  CAS  Google Scholar 

Cánepa ET, Scassa ME, Ceruti JM, Marazita MC, Carcagno AL, Sirkin PF, Ogara MF (2007) INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. IUBMB Life 59:419–426. https://doi.org/10.1080/15216540701488358

Article  PubMed  CAS  Google Scholar 

Coons SW, Johnson PC (1993) Regional Heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labeling index. J Neuropathol Exp Neurol 52:609–618. https://doi.org/10.1097/00005072-199311000-00008

Article  PubMed  CAS  Google Scholar 

Draaisma K, Tesileanu CMS, de Heer I, Klein M, Smits M, Reijneveld JC, Clement PM, de Vos FYF, Wick A, Mulholland PJ, Taphoorn MJB, Weller M, Chinot OL, Kros JM, Verschuere T, Coens C, Golfinopoulos V, Gorlia T, Idbaih A, Robe PA, van den Bent MJ, French PJ (2022) Prognostic significance of DNA methylation profiles at MRI enhancing Tumor recurrence: a report from the EORTC 26091 TAVAREC trial. Clin Cancer Res off J Am Assoc Cancer Res 28:2440–2448. https://doi.org/10.1158/1078-0432.CCR-21-3725

Article  CAS  Google Scholar 

Fortin Ensign SP, Jenkins RB, Giannini C, Sarkaria JN, Galanis E, Kizilbash SH (2023) Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma. Neuro-Oncol 25:28–36. https://doi.org/10.1093/neuonc/noac205

Article  PubMed  CAS  Google Scholar 

Geyer L, Wolf T, Chenard M-P, Cebula H, Schott R, Noel G, Guerin E, Pencreach E, Reita D, Entz-Werlé N, Lhermitte B (2023) p16 immunohistochemical expression as a Surrogate Assessment of CDKN2A Alteration in Gliomas leading to Prognostic significances. Cancers 15:1512. https://doi.org/10.3390/cancers15051512

Article  PubMed  PubMed Central  CAS  Google Scholar 

Guo X, Gu L, Li Y, Zheng Z, Chen W, Wang Y, Wang Y, Xing H, Shi Y, Liu D, Yang T, Xia Y, Li J, Wu J, Zhang K, Liang T, Wang H, Liu Q, Jin S, Qu T, Guo S, Li H, Wang Y, Ma W (2023) Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumors. Front Oncol 13:1200815. https://doi.org/10.3389/fonc.2023.1200815

Article  PubMed  PubMed Central  CAS  Google Scholar 

Harada H, Nakagawa K, Iwata S, Saito M, Kumon Y, Sakaki S, Sato K, Hamada K (1999) Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res 59:3783–3789

PubMed  CAS  Google Scholar 

Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, Von Deimling A (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol (Berl) 120:707–718. https://doi.org/10.1007/s00401-010-0781-z

Article  PubMed  Google Scholar 

Hickman RA, Gedvilaite E, Ptashkin R, Reiner AS, Cimera R, Nandakumar S, Price A, Vanderbilt C, Fahy T, Young RJ, Miller AM, Mellinghoff IK, Rosenblum MK, Ladanyi M, Arcila ME, Zhang Y, Brannon AR, Bale TA (2023) CDKN2A/B mutations and allele-specific alterations stratify survival outcomes in IDH-mutant astrocytomas. Acta Neuropathol (Berl) 146:845–847. https://doi.org/10.1007/s00401-023-02639-0

Article  PubMed  CAS  Google Scholar 

Higgins JP, Li T, Deeks JJ (2023) Chap. 6: Choosing effect measures and computing estimates of effect. In: Cochrane Handb. Syst. Rev. Interv. V64. https://training.cochrane.org/handbook/current/chapter-06. Accessed 22 Apr 2024

Hsu EJ, Thomas J, Maher EA, Youssef M, Timmerman RD, Wardak Z, Dan TD, Patel TR, Vo DT (2022) Impact of CDKN2A/B, MTAP, and TERT genetic alterations on Survival in IDH Wild Type Glioblastomas. Discov Oncol 13:126. https://doi.org/10.1007/s12672-022-00590-2

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kocakavuk E, Johnson KC, Sabedot TS, Reinhardt HC, Noushmehr H, Verhaak RGW (2023) Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas. Neuro-Oncol 25:1721–1723. https://doi.org/10.1093/neuonc/noad095

Article  PubMed  PubMed Central  Google Scholar 

Korshunov A, Casalini B, Chavez L, Hielscher T, Sill M, Ryzhova M, Sharma T, Schrimpf D, Stichel D, Capper D, Reuss DE, Sturm D, Absalyamova O, Golanov A, Lambo S, Bewerunge-Hudler M, Lichter P, Herold‐Mende C, Wick W, Pfister SM, Kool M, Jones DTW, Von Deimling A, Sahm F (2019) Integrated molecular characterization of IDH‐mutant glioblastomas. Neuropathol Appl Neurobiol 45:108–118. https://doi.org/10.1111/nan.12523

Article  PubMed  CAS  Google Scholar 

Liu N, Zhou Y, Lee JJ (2021) IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol 21:111. https://doi.org/10.1186/s12874-021-01308-8

Article  PubMed  PubMed Central  Google Scholar 

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, Von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the Central Nervous System: a summary. Neuro-Oncol 23:1231–1251. https://doi.org/10.1093/neuonc/noab106

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lu VM, O’Connor KP, Shah AH, Eichberg DG, Luther EM, Komotar RJ, Ivan ME (2020) The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature. J Neurooncol 148:221–229. https://doi.org/10.1007/s11060-020-03528-2

Article  PubMed  CAS  Google Scholar 

Maragkou T, Reinhard S, Jungo P, Pasquier B, Neuenschwander M, Schucht P, Vassella E, Hewer E (2023) Evaluation of MTAP and p16 immunohistochemical deficiency as surrogate marker for CDKN2A/B homozygous deletion in gliomas. Pathol (Phila) 55:466–477. https://doi.org/10.1016/j.pathol.2023.01.005

Article  CAS  Google Scholar 

Murnyak B, Huang LE (2021) Association of TP53 Alteration with tissue specificity and patient outcome of IDH1-Mutant glioma. Cells 10:2116. https://doi.org/10.3390/cells10082116

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS (2022) CBTRUS Statistical Report: primary brain and other Central Nervous System tumors diagnosed in the United States in 2015–2019. Neuro-Oncol 24:v1–v95. https://doi.org/10.1093/neuonc/noac202

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ozair A, Bhat V, Alisch RS, Khosla AA